Meeting Banner
Abstract #1841

The Diagnostic Value of PI-RADS V2 Scoring System Combining with MRI-TRUS Fusion Targeted Biopsy for Detecting the Clinical Significant Prostate Cancer

Jie Bao1, Xi-ming Wang1, Chun-hong Hu1, and Zhong-shuai Zhang2

1The First Affiliated Hospital of Soochow University, SUZHOU, China, 2MR Scientific Marketing, Siemens Healthcare, Shanghai, SHANG HAI, China

Transrectal ultrasound-guided systematic (TRUS) biopsy is commonly used in clinical practice to detect clinically significant prostate cancer (PCa)[1-3]. In this study, a more advanced biopsy, MRI-TRUS fusion targeted biopsy, is used together with MRI-derived PI-RADS V2 scoring system for the diagnosis of clinical significant PCa. The values of the two biopsy methods are compared.

This abstract and the presentation materials are available to members only; a login is required.

Join Here